title: [Bone and Calcium Research Update 2015. Novel treatment for FGF23-related hypophosphatemic diseases].
abstract: Fibroblast growth factor 23 (FGF23) is a hormone mainly produced by osteocytes and regulates phosphate and vitamin D metabolism by binding to Klotho-FGF receptor complex. Most diseases previously called vitamin D-resistant rickets/osteomalacia or familial hypophosphatemic rickets/osteomalacia have been shown to be caused by excess actions of FGF23. Therefore, several methods to inhibit the actions of FGF23 are now considered as new treatment methods for these FGF23-related hypophosphatemic diseases. It has been reported that anti-FGF23 antibody increases serum phosphate in patients with FGF23-related hypophosphatemic disease.
authors.affiliation: Fujii Memorial Institute of Medical Sciences, The University of Tokushima, Japan.
authors.forename: Seiji
authors.initials: S
authors.lastname: Fukumoto
mesh_terms: D000818:Animals; D000906:Antibodies / Q000627:therapeutic use; D001842:Bone and Bones / Q000378:metabolism*; D002118:Calcium / Q000378:metabolism*; D053098:Familial Hypophosphatemic Rickets / Q000276:immunology; D000089703:Fibroblast Growth Factor-23; D005346:Fibroblast Growth Factors / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D017674:Hypophosphatemia / Q000188:drug therapy* / Q000276:immunology
chemical_list: D000906:Antibodies; C000717427:FGF23 protein, human; D005346:Fibroblast Growth Factors; D000089703:Fibroblast Growth Factor-23; D002118:Calcium